Allemannsdata Wiki
Manual search

APIM THERAPEUTICS AS

Organization number 894298952 · Aksjeselskap

Programmatic access to company data (JSON)

Source: Firmafakta. Data read and page generated 2026-09-18T21:30:23Z. HTML cache: no-store (TTL 0 seconds). Default TTL for Firmafakta JSON/API responses: 60 seconds.

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:
894298952
navn:
APIM THERAPEUTICS AS
organisasjonsform:
kode:
AS
beskrivelse:
Aksjeselskap
naeringskode1:
kode:
46.460
beskrivelse:
Engroshandel med apotekvarer og medisinske varer
antallAnsatte:
not reported by source
hjemmeside:
not reported by source
epostadresse:
not reported by source
telefon:
not reported by source
forretningsadresse:
adresse:
c/o Sparebank 1 Regnskapshuset SMN, Yrjars gate 29
poststed:
BREKSTAD
postnummer:
7130
kommune:
ØRLAND
stiftelsesdato:
2009-06-18
registreringsdatoenhetsregisteret:
2009-08-29
aktivitet:
Utvikling, produksjon og markedsføring/salg av produkter/tjenester, innen legemidler, samt annen virksomhet som naturlig står i, tilknytning til dette.
vedtektsfestetFormaal:
Utvikling, produksjon og markedsføring/salg av produkter/tjenester, innen legemidler, samt annen virksomhet som naturlig står i, tilknytning til dette.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

Regnskapsfører

Revisor

Styre

Owners

Source: Firmafakta shareholder dataset.

Showing top 50 of 143 shareholders by holding size. Raise 'limit' (max 1000) for more.

  1. SARSIA SEED AS – 27.04 % (445067 shares, share class: NO0010734734)
  2. TROND MOHN FORSKNINGSSTIFTELSE – 18.26 % (300660 shares, share class: NO0010734734)
  3. INVESTINOR DIREKTE AS – 14.98 % (246528 shares, share class: NO0010734734)
  4. BIRK VENTURE AS – 2.96 % (48784 shares, share class: NO0010734734)
  5. ALTITUDE EXPLORER AS – 2.78 % (45760 shares, share class: NO0010734734)
  6. SKIPS AS TUDOR – 2.49 % (41040 shares, share class: NO0010734734)
  7. MARIT OTTERLEI – 2.13 % (35000 shares, share class: NO0010734734)
  8. KRAKR AS – 2.09 % (34326 shares, share class: NO0010734734)
  9. RO INVEST AS – 1.69 % (27807 shares, share class: NO0010734734)
  10. NORDA ASA – 1.55 % (25510 shares, share class: NO0010734734)
  11. JENS PETTER RØNNING – 1.52 % (25000 shares, share class: NO0010734734)
  12. HMH INVEST AS – 1.28 % (21048 shares, share class: NO0010734734)
  13. H5 VEKST AS – 1.13 % (18600 shares, share class: NO0010734734)
  14. CHAMAR AS – 1.12 % (18435 shares, share class: NO0010734734)
  15. HELIFT AS – 1.06 % (17492 shares, share class: NO0010734734)
  16. VENTOR AS – 0.93 % (15333 shares, share class: NO0010734734)
  17. TELEVENTURE MANAGEMENT XI AS – 0.74 % (12147 shares, share class: NO0010734734)
  18. PRIVATE EQUITY GROWTH 2012 AS – 0.73 % (12071 shares, share class: NO0010734734)
  19. IFE INVEST AS – 0.72 % (11899 shares, share class: NO0010734734)
  20. GLOBAL OPPORTUNITIES PE AS – 0.71 % (11755 shares, share class: NO0010734734)
  21. SPAREBANK 1 SMN INVEST AS – 0.52 % (8622 shares, share class: NO0010734734)
  22. TELEVENTURE CAPITAL AS – 0.52 % (8622 shares, share class: NO0010734734)
  23. FLC INVESTMENTS AS – 0.52 % (8493 shares, share class: NO0010734734)
  24. HELIFT AS – 0.47 % (7760 shares, share class: NO0010734734)
  25. NTNU TECHNOLOGY TRANSFER AS – 0.46 % (7616 shares, share class: NO0010734734)
  26. EMADOLDIN FEYZI TALARPOSHTI – 0.46 % (7500 shares, share class: NO0010734734)
  27. PER ARNE AAS – 0.46 % (7500 shares, share class: NO0010734734)
  28. BJELLAND CAPITAL I AS – 0.44 % (7289 shares, share class: NO0010734734)
  29. ABRAXAS AS – 0.42 % (6933 shares, share class: NO0010734734)
  30. KARLANDER INVEST AS – 0.41 % (6745 shares, share class: NO0010734734)
  31. AKERSHUS TEKNOLOGIFOND AS – 0.4 % (6568 shares, share class: NO0010734734)
  32. TORSEN TANKERS & TOWERS AS – 0.34 % (5530 shares, share class: NO0010734734)
  33. KOLBERG MOTORS AS – 0.24 % (4023 shares, share class: NO0010734734)
  34. F600 INVEST AS – 0.23 % (3837 shares, share class: NO0010734734)
  35. OSKAR INVESTMENT AS – 0.22 % (3570 shares, share class: NO0010734734)
  36. LEMICA AS – 0.2 % (3305 shares, share class: NO0010734734)
  37. HARMONIUM INVEST AS – 0.2 % (3275 shares, share class: NO0010734734)
  38. HERING AS – 0.19 % (3063 shares, share class: NO0010734734)
  39. ANELSEN AS – 0.18 % (2975 shares, share class: NO0010734734)
  40. ESMAR AS – 0.18 % (2893 shares, share class: NO0010734734)
  41. GJERDINGEN AS – 0.17 % (2874 shares, share class: NO0010734734)
  42. SAUAR INVEST AS – 0.17 % (2819 shares, share class: NO0010734734)
  43. ROCK DOVE HOLDINGS LIMITED – 0.17 % (2745 shares, share class: NO0010734734)
  44. JENSSEN & CO AS – 0.15 % (2472 shares, share class: NO0010734734)
  45. BERNHD. BREKKE A/S – 0.15 % (2443 shares, share class: NO0010734734)
  46. TORKAP AS – 0.15 % (2443 shares, share class: NO0010734734)
  47. CLARIN AS – 0.14 % (2342 shares, share class: NO0010734734)
  48. JAMA HOLDING AS – 0.14 % (2227 shares, share class: NO0010734734)
  49. MOLVER AS – 0.13 % (2213 shares, share class: NO0010734734)
  50. OSJO HOLDING AS – 0.13 % (2213 shares, share class: NO0010734734)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (0)

No registered grants.

EU-tildelinger (0)

No registered grants.

Forskningsrådet (2)

2 results

  1. id:
    1532
    prosjektnummer:
    228544
    prosjekttittel:
    ATX-101: A novel peptide drug for the treatment of bladder cancer
    prosjektstart:
    2013
    prosjektslutt:
    2016
    prosjektansvarlig_navn:
    APIM THERAPEUTICS AS
    organisasjonsnummer:
    894298952
    sokt_belop:
    Bioteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  2. id:
    21374
    prosjektnummer:
    210547
    prosjekttittel:
    Research and Development of APIM anti-cancer drug
    prosjektstart:
    2011
    prosjektslutt:
    2013
    prosjektansvarlig_navn:
    APIM THERAPEUTICS AS
    organisasjonsnummer:
    894298952
    sokt_belop:
    Bioteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer

SkatteFUNN (9)

9 results

  1. id:
    45552
    innsendt_dato:
    2017-08-30
    prosjektnummer:
    278236
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Phase I/IIa clinical evaluation of the novel peptide drug ATX-101 in patients with advanced cancer.
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2017-09-15
    prosjekt_fra_ar:
    2017
    prosjekt_til_ar:
    2018
    sammendrag:
    not reported by source
  2. id:
    62997
    innsendt_dato:
    2021-08-31
    prosjektnummer:
    330390
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    ATX-101 pharmaceutical product development
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-09-14
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2022
    sammendrag:
    APIM Therapeutics is currently developing ATX-101, an investigational anti-cancer agent based on a novel mechanism of action highly relevant for cancer escape and resistance. ATX-101 has recently been tested in a first-in-human phase 1 clinical study in advanced cancer patients and will soon enter subsequent clinical testing in ovarian cancer and sarcoma. Preparing for expanded clinical development activities that increase the needs for drug supplies and cost-effective patient dosing, the aim of the current project is to further optimize current drug manufacturing processes to deliver drug amounts in the kg scale. Furthermore, it focuses on developing new drug product strengths that reduce waste and translate in significant cost-of good reductions. Finally, new drug analysis methods required for subsequent clinical development activities as per regulatory standards will also be validated. Collectively, this work will expand the proprietary knowledge and know-how of the company and will contribute to further product de-risking and company value creation.
  3. id:
    50185
    innsendt_dato:
    2018-08-29
    prosjektnummer:
    292240
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Phase I/IIa clinical evaluation of the novel peptide drug ATX-101 in patients with advanced cancer.
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2018-09-13
    prosjekt_fra_ar:
    2018
    prosjekt_til_ar:
    2020
    sammendrag:
    APIM Therapeutics is currently developing ATX-101, an investigational anti-cancer agent based on a novel mechanism of action highly relevant for cancer escape and resistance. In preclinical studies, ATX-101 potentiates the actions of several anti-cancer agents across multiple solid tumor indications. Moreover, it shows single agent activity in blood cancers such as multiple myeloma. Having successfully completed all regulatory authority-mandated safety and toxicology studies, ATX-101 will enter first-in-man clinical testing in 2018. This testing aims to provide pivotal safety and efficacy data on ATX-101 and its mechanism of action as required for its continuous clinical development. The first trial to be conducted involves patients with advanced solid tumors (phase I). Upon conclusion of the first phase I part, a subsequent trial extension arm is planned in patients with advanced multiple myeloma (phase IIa). Following these initial trials, ATX-101 will enter subsequent clinical testing targeting as lead indications metastatic bladder cancer and multiple myeloma.
  4. id:
    62780
    innsendt_dato:
    2021-08-27
    prosjektnummer:
    330162
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Phase 1b clinical trial of ATX-101 in combination with chemotherapy in ovarian cancer patients
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-09-10
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2023
    sammendrag:
    APIM Therapeutics is currently developing ATX-101, an investigational anti-cancer agent based on a novel mechanism of action highly relevant for cancer escape and resistance. In preclinical studies, ATX-101 shows single agent activity and potentiation of the action of several anti-cancer agents, including platinum-based chemotherapy, across multiple tumor indications. After successfully completing preclinical development, ATX-101 has been tested in a first-in-human phase 1 clinical study in advanced cancer patients. The study has proven the excellent safety profile of the drug and provided indications of clinical activity in patients. Based on these results, the company is planning to conduct a phase 1b clinical study in patients with ovarian cancer. The study will assess the safety of increasing doses of ATX1-101 combined with a platinum-based standard of care treatment in this indication (carboplatin/pegylated liposomal doxorubicin). Additional efficacy, pharmacokinetic and mechanistic analyses will also be conducted. The planned study is expected to further validate the company's novel therapeutic approach and catalyze future clinical development of the specific ATX-101 combination in this cancer indication.
  5. id:
    62781
    innsendt_dato:
    2021-08-27
    prosjektnummer:
    330163
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Phase 2 study to evaluate ATX-101 in advanced sarcoma patients.
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-09-10
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2022
    sammendrag:
    APIM Therapeutics is currently developing ATX-101, an investigational anti-cancer agent based on a novel mechanism of action highly relevant for cancer escape and resistance. In preclinical studies, ATX-101 shows single agent activity and potentiation of the action of several anti-cancer agents across multiple tumor indications. After successfully completing preclinical development, ATX-101 has been tested in a first-in-human phase 1 clinical study in advanced cancer patients. The study has proven the excellent safety profile of the drug and provided indications of clinical activity in patients. These included two patients with sarcoma one of which was treated with ATX-101 for over 15.6 months and remained stable 2.4 years after the start of ATX-101 treatment. These results together with promising preclinical results obtained in a series of patient-derived sarcoma cell lines conducted in collaboration with Columbia University, US resulted in a decision to pursue further clinical and preclinical work in this indication. The current project is therefore based on new sarcoma-specific drug development of the company’s drug ATX-101 hoping to address the high unmet medical need in these patients. Overall, the planned study is expected to further validate the company's novel therapeutic approach and catalyze future clinical development of ATX-101 in this cancer indication.
  6. id:
    40485
    innsendt_dato:
    2016-08-25
    prosjektnummer:
    264779
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Development of a novel peptide drug for the treatment of bladder cancer (ATX-101)
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2016-08-26
    prosjekt_fra_ar:
    2016
    prosjekt_til_ar:
    2016
    sammendrag:
    not reported by source
  7. id:
    68605
    innsendt_dato:
    2023-08-31
    prosjektnummer:
    348324
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Long term follow up of ovarian cancer patients treated with ATX-101 in combination with chemotherapy
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2023-11-17
    prosjekt_fra_ar:
    2023
    prosjekt_til_ar:
    2024
    sammendrag:
    APIM Therapeutics is currently developing ATX-101, an investigational anti-cancer agent based on a novel mechanism of action highly relevant for cancer escape and resistance. In preclinical studies, ATX-101 shows single agent activity and potentiation of the action of several anti-cancer agents, including platinum-based chemotherapy, across multiple tumor indications. After successfully completing preclinical development, ATX-101 has been tested in a first-in-human phase 1 clinical study in advanced cancer patients. The study has proven the excellent safety profile of the drug and provided indications of clinical activity in patients. In a subsequent phase 1b study conducted in ovarian cancer patients, ATX-101 dosed in combination with platinum based chemotherapy for 6 months, was shown to be safe. Furthermore, the combination showed clinical activity. In this project, the company is aiming to evaluate long-term effects of the treatment in the cohort of 16 patients already dosed in the phase 1b study. The study will therefore assess the progression free survival of patients for a period of up to 20 months. The planned study is expected to further validate the company's novel therapeutic approach and catalyze future clinical development of the specific ATX-101 combination in this cancer indication.
  8. id:
    24583
    innsendt_dato:
    2010-08-26
    prosjektnummer:
    206183
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Utvikling av APIM kreftmedisin
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2010-11-11
    prosjekt_fra_ar:
    2010
    prosjekt_til_ar:
    2012
    sammendrag:
    not reported by source
  9. id:
    31341
    innsendt_dato:
    2013-08-31
    prosjektnummer:
    233176
    bedriftsnavn:
    APIM THERAPEUTICS AS
    prosjekttittel:
    Development of a novel peptide drug for the treatment of bladder cancer (ATX-101)
    organisasjonsnummer:
    894298952
    fylke:
    Trøndelag - Trööndelage
    kommunenavn:
    Indre Fosen
    poststed:
    RISSA
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2013-10-22
    prosjekt_fra_ar:
    2013
    prosjekt_til_ar:
    2015
    sammendrag:
    not reported by source

Subunits

Open positions

count:
0
stillinger:

No results.

Related lookups

How an AI agent should use this page

Ground rule: Navigate with HTML GET links to keep explanations and relationships. Use the page's JSON alternative only when concrete values must be extracted, compared or computed.

How to use the company page

  1. Use the organization number as the stable key.
  2. Distinguish between the company's own facts, roles, owners, holdings and grants.
  3. Follow person and company links to explore the graph; do not assume relations that are not explicitly registered.

Related services

Time: Ownership, roles and status can change. State the source and retrieval time with factual claims.

AI agent? Read the complete navigation and programming guide.